Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

NCT05422183 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer, Epithelial

Interventions

DRUG: Envafolimab
DRUG: Lenvatinib
DRUG: VP-16

Sponsor

Zhongda Hospital